

FOR IMMEDIATE RELEASE

December 1, 2025
Business Engineering Corporation

B-EN-G Announces Capital Investment in Thailand-Based BatchLine Co., Ltd.

**Accelerating Global Expansion of Digital Transformation (DX) Solutions
for Pharmaceutical Manufacturing with an Investment up to JPY 100
Million**

TOKYO, Japan – Business Engineering Corporation (Headquarters: Chiyoda-ku, Tokyo; President & CEO: Masakazu Haneda; hereinafter “B-EN-G”) announced on November 27, 2025 its decision to make a capital investment in BatchLine Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: David Margetts; hereinafter “BatchLine”).

B-EN-G plans to initially subscribe to a third-party allotment of new shares in BatchLine, up to JPY 100 million.

This capital participation will enable both companies to reinforce their system for providing **electronic batch manufacturing record solutions**, accelerating the Digital Transformation (DX) for LifeScience manufacturers in the global market.

Background

In the LifeScience manufacturing industry, the digitalization of manufacturing records is an urgent necessity, driven by the critical requirements of data integrity and GMP compliance.

B-EN-G established a partnership with BatchLine in January 2025 and began offering BatchLine’s **BatchLine MES** solution in the Japanese market in March. Through subsequent sales activities, B-EN-G has confirmed the strong market potential of the product, particularly among small to mid-sized LifeScience companies seeking digital solutions for **MBR (Master Batch Record)** and **EBR (Electronic Batch Record)** that fit their budget.

Furthermore, with the rapidly expanding demand for LifeScience manufacturing DX in the global market, strengthening deployment in the Asian and Western markets is essential. B-EN-G decided on this strategic capital investment to deepen its partnership with BatchLine and enhance its competitive edge in the global arena.

Personal statements:

"We are truly excited to further deepen our relationship with B-EN-G, having worked alongside them as partners for many years. We understand and appreciate the assets they have in terms of people, solutions, and market access, and look forward to executing our shared vision for new approaches to MES in the pharmaceutical industry together". - David Margetts representing BatchLine

Significance of the Capital Investment

This capital participation aims to achieve the following three key objectives:

1. **Accelerated Global Business Expansion** By leveraging B-EN-G's overseas subsidiary network and BatchLine's global customer base, we will accelerate the worldwide deployment of electronic manufacturing record solutions for the LifeScience industry.
2. **Enhanced Product Development and Service Delivery** Both companies will effectively coordinate their development resources to expand product features and elevate service quality. Specifically, the combination of B-EN-G's deep expertise in the LifeScience sector and BatchLine's **SaaS development technology** will allow us to offer comprehensive solutions.
3. **Deepening of Strategic Partnership** The solid partnership established through this capital tie-up enables the formulation and execution of long-term business plans. Additionally, by combining BatchLine's solution with B-EN-G's various offerings, we can provide comprehensive support for the overall DX of the LifeScience manufacturing floor.

Future Outlook

Through this capital participation, both companies aim to establish a position as a **global leader in solutions for the LifeScience manufacturing industry**.

By leveraging our shared **expertise** in LifeScience manufacturing and the combined strength of **B-EN-G's solutions and BatchLine's offerings**, we will contribute to the **enhancement of drug availability, quality, regulatory compliance, and productivity**.

B-EN-G will continue to actively pursue strategic capital alliances to support the digital transformation of our customers, especially in the manufacturing sector, thereby enhancing corporate value.

About BatchLine Co., Ltd.

BatchLine is a provider of Manufacturing Execution Systems (MES) for the LifeScience industry. Its MES solutions are designed to support the electronification

and efficiency of manufacturing processes and strengthen **regulatory compliance**. The company provides flexible and comprehensive solutions tailored to the unique needs of the LifeScience sector, earning high praise from global LifeScience companies.

About Business Engineering Corporation (B-EN-G)

Business Engineering Corporation (B-EN-G) supports the digital transformation of its customers, primarily in the manufacturing sector, through IT. The company has extensive experience in consulting and support services, from IT planning to system construction, implementation, and operation, as well as the sales and implementation of its proprietary package software, "**mcframe**." B-EN-G also helps customers advance their systems and improve operations by utilizing data accumulated from ERP, SCM, IoT, and other systems. With five overseas subsidiaries in China (Shanghai), Thailand (Bangkok), Singapore, Indonesia (Jakarta), and the USA (Chicago), B-EN-G offers products and services to global companies, working closely with them both in Japan and locally to resolve their management challenges. For more information about Business Engineering Corporation, please visit <https://www.b-en-g.co.jp/>.

Inquiries regarding this solution:

Business Engineering Corporation, Solution Business Division, Sales Department
E-mail: solution-info@b-en-g.co.jp

inquiries about this press release

Business Engineering Corporation, Public Relations
E-mail: kouhou@b-en-g.co.jp

Note: All product names and names mentioned in this release are the trademarks or registered trademarks of their respective companies.